摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3,5-二甲基-1H-吡唑-4-基)-乙酸叔丁酯 | 1082827-81-3

中文名称
(3,5-二甲基-1H-吡唑-4-基)-乙酸叔丁酯
中文别名
(3,5-二甲基-1H-吡咯-4-基)-乙酸叔丁酯
英文名称
(3,5-dimethyl-1H-pyrazol-4-yl)-acetic acid tert-butyl ester
英文别名
(3,5-dimethyl-1H-pyarzol-4-yl)acetic acid tert butyl ester;tert-butyl 2-(3,5-dimethyl-1H-pyrazol-4-yl)acetate;1,1-dimethylethyl (3,5-dimethyl-1H-pyrazol-4-yl)acetate;tert-butyl (3,5-dimethyl-1H-pyrazol-4-yl)acetate
(3,5-二甲基-1H-吡唑-4-基)-乙酸叔丁酯化学式
CAS
1082827-81-3
化学式
C11H18N2O2
mdl
——
分子量
210.276
InChiKey
NHPZJVXDBAQQMI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    15
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.64
  • 拓扑面积:
    55
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 危险性防范说明:
    P264,P280,P302+P352,P305+P351+P338,P332+P313,P337+P313,P362
  • 危险性描述:
    H315,H319

反应信息

  • 作为反应物:
    参考文献:
    名称:
    2-(1H-Pyrazol-4-yl)acetic acids as CRTh2 antagonists
    摘要:
    High throughput screening identified the pyrazole-4-acetic acid substructure as CRTh2 receptor antagonists. Optimisation of the compounds uncovered a tight SAR but also identified some low nanomolar inhibitors. (C) 2013 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2013.03.093
  • 作为产物:
    描述:
    3-乙酰基-4-氧代戊酸叔丁酯一水合肼 作用下, 以 溶剂黄146 为溶剂, 反应 1.0h, 以98%的产率得到(3,5-二甲基-1H-吡唑-4-基)-乙酸叔丁酯
    参考文献:
    名称:
    [EN] NEW PYRAZOLE DERIVATIVES HAVING CRTH2 ANTAGONISTIC BEHAVIOUR
    [FR] NOUVEAUX DÉRIVÉS DE PYRAZOLE POSSÉDANT UN COMPORTEMENT ANTAGONISTE DE CRTH2
    摘要:
    本发明涉及一种式(I)的化合物,以及制备这种化合物的方法,以及它们在治疗病理状况或疾病中的应用,这些病理状况或疾病容易通过CRTh2拮抗活性得到改善。
    公开号:
    WO2012069175A1
点击查看最新优质反应信息

文献信息

  • [EN] PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS<br/>[FR] COMPOSÉS PYRAZOLES COMME ANTAGONISTES DU CRTH2
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2012130633A1
    公开(公告)日:2012-10-04
    The present invention relates to pyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof having CRTH2 antagonistic activity, wherein L, Y1, Y2, Y3, Y4, Y5, Z, R1, R2, R3 and n have one of the meanings as indicated in the specification and claims, to their use as medicaments, to pharmaceutical compositions containing said compounds and to pharmaceutical compositions containing said compounds in combination with one or more active substances.
    本发明涉及具有CRTH2拮抗活性的式(I)的吡唑化合物及其药学上可接受的盐,其中L、Y1、Y2、Y3、Y4、Y5、Z、R1、R2、R3和n具有规范和索赔中指示的含义之一,以及它们作为药物的用途,含有所述化合物的药物组合物,以及含有所述化合物与一个或多个活性物质的药物组合物。
  • New pyrazole derivatives having CRTh2 antagonistic behaviour
    申请人:Almirall, S.A.
    公开号:EP2457900A1
    公开(公告)日:2012-05-30
    The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.
    这项发明涉及一种化合物的公式(I),以及制备这种化合物的方法,以及它们在治疗病理状况或疾病中的应用,这些病理状况或疾病容易通过CRTh2拮抗活性得到改善。
  • [EN] 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] COMPOSÉS DE 4-OXO-3,4-DIHYDROQUINAZOLINE UTILISÉS EN TANT QU'INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
    申请人:VIIV HEALTHCARE UK NO 5 LTD
    公开号:WO2019198024A1
    公开(公告)日:2019-10-17
    Compounds of Formula (I), including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: Formula (I):
    化合物的公式(I),包括其药用盐,以及用于治疗人类免疫缺陷病毒(HIV)感染的组合物和方法如下:公式(I):
  • [EN] PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS<br/>[FR] COMPOSÉS PYRAZOLE COMME ANTAGONISTES DU CRTH2
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2011092140A1
    公开(公告)日:2011-08-04
    The present invention relates to pyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof having CRTH2-activity, wherein W, L1, L2, X, L3, Y, R1 and R2 are as defined in the specification and claims, to their use as medicaments and to pharmaceutical formulations, containing said compounds or containing a combination of said compounds with one or more active substances.
    本发明涉及具有CRTH2活性的式(I)的吡唑化合物及其药学上可接受的盐,其中W、L1、L2、X、L3、Y、R1和R2如规范和索赔中定义,其用作药物和含有该化合物或与一个或多个活性物质的组合物的药物配方。
  • PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS
    申请人:OOST Thorsten
    公开号:US20120028938A1
    公开(公告)日:2012-02-02
    The present invention relates to pyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof having CRTH2-activity, wherein W, L 1 , L 2 , X, L 3 , Y, R 1 and R 2 are as defined in the specification and claims, to their use as medicaments and to pharmaceutical formulations, containing said compounds or containing a combination of said compounds with one or more active substances.
    本发明涉及具有CRTH2活性的式(I)的吡唑化合物及其药学上可接受的盐,其中W、L1、L2、X、L3、Y、R1和R2如规范和索赔中所定义,以及它们作为药物的用途和包含该化合物或包含该化合物与一种或多种活性物质的组合物的制药配方。
查看更多